Source link : https://www.newshealth.biz/health-news/belimumab-hits-newer-remission-low-disease-activity-metrics/
TOPLINE: A greater proportion of patients with active systemic lupus erythematosus (SLE) treated with belimumab plus standard therapy achieved the newest definitions for remission and low disease activity compared with those treated with placebo plus standard therapy, with benefits observed as early as week 28 for remission and week 8 for disease activity, according to […]
Author : News Health
Publish date : 2024-09-12 13:03:50
Copyright for syndicated content belongs to the linked Source.